IRVINE, Calif., July 28, 2021 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the first patient has been dosed in the STRIDE study. The trial is designed to evaluate the efficacy and safety of REN001 for the treatment of patients with primary mitochondrial myopathies (PMM).
STRIDE is a global, double-blind, randomized, placebo-controlled Phase 2b trial designed to assess the efficacy and safety of 100 mg REN001 administered orally, once-daily for 24 weeks. Approximately 200 adult patients with PMM caused by alterations in mitochondrial DNA are expected to be enrolled into STRIDE. The primary efficacy endpoint is the change from baseline in the distance walked during a 12-minute walk test after 24 weeks of treatment. Secondary efficacy endpoints include changes from baseline in the Modified Fatigue Impact Scale, Patient Global Impression of Change scale, and other patient-reported outcomes.
Click here for the full article.